Investment Thesis
COMPASS Pathways is a pre-commercial clinical-stage biopharmaceutical company with zero revenue and negative operating cash flow of -$47.9M annually. While the company maintains a fortress balance sheet with $466M in cash and minimal debt, it is purely executing on R&D with no near-term profitability path and faces significant regulatory approval risk on psilocybin therapies.
Strengths
- Exceptional cash reserves of $466M provide 10+ year runway at current burn rate
- Very strong balance sheet with 0.15x debt-to-equity ratio and 3.32x current ratio
- Positioned in high-growth psychedelic-assisted therapy market with significant unmet medical need
Risks
- Zero revenue with company in pre-commercial clinical development stage
- Negative operating cash flow of -$47.9M; company burning cash with no offsetting revenue
- Regulatory uncertainty for psilocybin therapies; approval not guaranteed and timelines unpredictable
- Negative EPS trends (-0.30, down 33.9% YoY) with no clear profitability inflection point
- Dilutive equity financing likely required if development timelines extend or commercialization is delayed
Key Metrics to Watch
- Clinical trial progress and regulatory pathway updates for COMP360 psilocybin therapy
- Quarterly cash burn rate and cash runway (currently consuming ~$48M annually)
- R&D spend efficiency and timeline to potential FDA approval or license agreements
Financial Metrics
Revenue
N/A
Net Income
91.2M
EPS (Diluted)
$-0.30
Free Cash Flow
-47.9M
Total Assets
531.7M
Cash
466.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
27.9%
ROA
17.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
3.32x
Quick Ratio
3.32x
Debt/Equity
0.15x
Debt/Assets
38.6%
Interest Coverage
-28.60x
Long-term Debt
50.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:59:55.440187 |
Data as of: 2026-03-31 |
Powered by Claude AI